Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 159

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 159
---

    1,452,502

    Accumulated other comprehensive gain

    166

    215

    Accumulated deficit

    (1,303,824
    )

    (1,144,332
    )

    Total Adaptive Biotechnologies Corporation shareholders’ equity

    202,709

    308,399

    Noncontrolling interest

    (224
    )

    (121
    )

    Total shareholders’ equity

    202,485

    308,278

    Total liabilities and shareholders’ equity
     
    $
    539,376

    $
    661,134

The accompanying notes are an integral part of these consolidated financial statements.

91

Adaptive Biotechnologies Corporation

Consolidated Statements of Operations

(in thousands, except share and per share amounts)

    Year Ended December 31,

    2024

    2023

    2022

    Revenue
     
    $
    178,957

    $
    170,276

    $
    185,308

    Operating expenses

    Cost of revenue

    72,080

    75,553

    57,909

    Research and development

    102,953

    122,117

    141,756

    Sales and marketing

    84,759

    88,579

    95,603

    General and administrative

    72,806

    83,934

    88,527

    Amortization of intangible assets

    1,703

    1,699

    1,699

    Impairment of long-lived assets

    7,205

    25,429

    —

    Total operating expenses

    341,506

    397,311

    385,494

    Loss from operations

    (162,549
    )

    (227,035
    )

    (200,186
    )

    Interest and other income, net

    14,534

    15,531

    4,056

    Interest expense

    (11,580
    )

    (13,800
    )

    (4,238
    )

    Net loss

    (159,595
    )

    (225,304
    )

    (200,368
    )

    Add: Net loss attributable to non